title: E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy.
abstract: E3 ubiquitin ligase Skp2 attaches ubiquitin to its target proteins and marks them for destruction by the 26S proteasome. This mechanism participates in a number of important cellular processes such as cell proliferation, DNA replication, V(D)J recombination, gene transcription, cellular metabolism and senescence. Skp2 is oncogenic. It is overexpressed in various solid tumors and hematological malignancies. Due to the antagonistic role Skp2 plays against p27, Skp2 overexpression is frequently associated with down-regulation of p27. Importantly, Skp2 overexpression in cancer cells is prognostic of cancer progression and overall survival. Recent studies have shown that Skp2 suppression might be an excellent strategy to inhibit tumorigenesis in tumors in which tumor suppressor genes such as VHL, RB or TP53 are mutated. In this review, we also summarize early efforts in the development of Skp2 inhibitors. The implications of continued, long-term Skp2 suppression is discussed.
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Medical College of Georgia, Georgia Regents University, Augusta, GA30912.
authors.forename: Zhonglin
authors.initials: Z
authors.lastname: Hao
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Medical College of Georgia, Georgia Regents University, Augusta, GA30912.
authors.forename: Shuang
authors.initials: S
authors.lastname: Huang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D063646:Carcinogenesis; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000517:prevention & control; D044786:S-Phase Kinase-Associated Proteins / Q000378:metabolism*; D054875:Ubiquitination
chemical_list: D000970:Antineoplastic Agents; D044786:S-Phase Kinase-Associated Proteins